Diffuse intrinsic pontine glioma

This phase 1 trial tests a new approach for diffuse midline glioma (DMG), an aggressive brain tumor with a poor prognosis. The treatment combines focused ultrasound to temporarily open the blood-brain barrier with an infusion of immune cells engineered to attack the tumor. The st…

This trial is testing whether a new formulation of the chemotherapy drug cisplatin, called LSAM-Cisplatin, can be safely infused directly into the brain tumors of children and young adults with diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG). The t…

This study tests a custom-made vaccine for people with two serious brain cancers: glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). The vaccine is made from the patient's own immune cells and designed to teach the body to attack the tumor. The main goals are to chec…

This early-phase study tests a new treatment for children and young adults with aggressive brain tumors called high-grade glioma and DIPG. The therapy uses the patient's own immune cells, modified in a lab to better recognize and attack tumor cells. The main goals are to see if t…

This study is for adolescents and young adults (ages 12-39) newly diagnosed with aggressive brain tumors called high-grade glioma or DIPG. The goal is to see if a combination of two immunotherapy drugs (relatlimab and nivolumab, sold as Opdualag) is safe and tolerable when given …

This study tests a new treatment called 4sCAR-DLL3 CAR-T cells for people with DLL3-positive brain tumors, including glioblastoma and certain midline gliomas. The therapy uses a patient's own immune cells, modified to target and attack tumor cells. The trial will enroll 30 partic…

This study tests a new therapy using a patient's own immune cells, engineered to target a specific mutation found in diffuse midline glioma and DIPG, aggressive brain tumors. About 30 participants with recurrent or refractory disease will receive one to two infusions of these cel…

This study tests a drug called tovorafenib in children and young adults (ages 1 to 39) newly diagnosed with aggressive brain tumors (high-grade glioma or DIPG) that have specific genetic changes. The goal is to see if the drug can help them live longer. About 79 participants will…

This early-stage study tests a new drug called FZ-AD005 in 40 people with aggressive brain tumors (high-grade glioma) that have come back or not responded to treatment. The drug is designed to target and kill cancer cells while sparing healthy ones. The main goals are to find the…

This early-stage study tests an experimental drug called gallium maltolate in 15 children whose high-grade glioma or atypical teratoid rhabdoid tumor has returned or not responded to treatment. The main goals are to find safe doses and understand side effects. Everyone receives t…

This phase 3 trial tests whether adding two experimental drugs (Atengenal and Astugenal) to standard radiation affects heart rhythm in children aged 3–21 with newly diagnosed diffuse intrinsic brainstem glioma. The study will enroll 30 participants and monitor heart electrical ac…

This phase 3 trial tests whether adding two experimental drugs (Atengenal and Astugenal) to standard radiation therapy helps people aged 3 and older with a newly diagnosed, aggressive brainstem tumor live longer. About 92 participants will be randomly assigned to get either radia…